Pic Therapeutics
Biotechnology, 27 Strathmore Rd, Natick, Massachusetts, 01760, United States, 1-10 Employees
Phone Number: 16*********
Who is PIC THERAPEUTICS
PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation...
Read More
-
Headquarters: 27 Strathmore Rd, Natick, Massachusetts, 01760, United States
-
Date Founded: 2016
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 5122
Does something look wrong? Fix it. | View contact records from PIC THERAPEUTICS
PIC Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding PIC Therapeutics
Answer: PIC Therapeutics's headquarters are located at 27 Strathmore Rd, Natick, Massachusetts, 01760, United States
Answer: PIC Therapeutics's phone number is 16*********
Answer: PIC Therapeutics's official website is https://pictherapeutics.com
Answer: PIC Therapeutics's revenue is Under $1 Million
Answer: PIC Therapeutics's SIC: 5122
Answer: PIC Therapeutics has 1-10 employees
Answer: PIC Therapeutics is in Biotechnology
Answer: PIC Therapeutics contact info: Phone number: 16********* Website: https://pictherapeutics.com
Answer: PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation. PIC Therapeutics was founded on the seminal work of Dr. Gerhard Wagner, a professor at Harvard Medical School world-renowned for his scientific expertise in protein structure and his research on interactions of eukaryotic translation initiation factors (eIFs). PIC Therapeutics, led by President and CEO Dr. Kathy Bowdish, was launched to translate these discoveries into small molecule precision therapeutics to benefit cancer patients. Our precision-based therapeutics target the master switch of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Our selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month